November 7, 2014 — Lantheus Medical Imaging Inc. and Shine Medical Technologies Inc. announced that the companies have entered into a strategic agreement for the future supply of molybdenum-99 (Mo-99). The supply agreement marks Lantheus’ first with a prospective United States supplier of Mo-99.
Under the terms of the supply agreement, Shine will provide Mo-99 produced using its proprietary low-enriched uranium (LEU)-solution technology for use in Lantheus’ TechneLite (Technetium Tc99m Generator) generators once Shine’s facility becomes operational and receives all necessary regulatory approvals, which Shine estimates will occur in early 2018. Mo-99 is the parent isotope of technetium-99m (Tc-99m), an essential tracer in a variety of diagnostic tests and the most widely used isotope in nuclear medicine.
Currently, Lantheus receives Mo-99 from four of the five major processors and seven of the eight associated reactors. As the medical imaging community moves toward LEU-based Mo-99 supply, Lantheus' LEU TechneLite generator and gradual conversion to a 100-percent LEU-derived Mo-99 supply chain ensures that Lantheus customers will have access to Tc-99m now and in the future.
For more information: www.lantheus.com
July 30, 2024 
